LCP
BMY.RT

Legacy Capital Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Legacy Capital Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-14,367
Closed -$10K – 145
2020
Q4 		$10K Sell
14,367
-1,600
-10% -$3.41K ﹤0.01% 135
2020
Q3 		$36K Buy
+15,967
New +$45.6K 0.01% 134

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Legacy Capital Partners's BMY.RT Position: Q1 2021 in Review

Legacy Capital Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 14,367 shares — an estimated $10K sold.

Legacy Capital Partners first reported a position in BMY.RT in Q3 2020 and held it in 2 quarters. The position peaked at $36K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Legacy Capital Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Legacy Capital Partners sold 14,367 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $10K.
  • Legacy Capital Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q3 2020 and held it in 2 quarters.
  • Legacy Capital Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $36K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Legacy Capital Partners's 13F filing for Q1 2021, filed 20 Apr 2021.